No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial

Autor: Alain Kentos, Julie Dechene, Pauline Brice, Olivier Casasnovas, Yvon Englert, Viviane De Maertelaer, Isabelle Demeestere, Dominique Bron, Fedro A. Peccatori, Eric Van Den Neste, Jehan Dupuis, Pierre Zachee
Rok vydání: 2016
Předmět:
Adult
Fertility -- drug effects
Agonist
Oncology
endocrine system
Cancer Research
medicine.medical_specialty
endocrine system diseases
medicine.drug_class
Ovary -- drug effects -- physiology
Gonadotropin-Releasing Hormone -- agonists
Gonadotropin-releasing hormone
law.invention
03 medical and health sciences
Gynécologie
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
Gonadotropin-releasing hormone agonist
Norethindrone -- therapeutic use
medicine
Humans
Prospective Studies
Fertility preservation
Prospective cohort study
Ovarian reserve
Primary Ovarian Insufficiency -- prevention & control
Gynecology
030219 obstetrics & reproductive medicine
business.industry
Fertility Preservation -- methods
Lymphoma -- drug therapy
Middle Aged
medicine.disease
female genital diseases and pregnancy complications
Premature ovarian failure
Cancérologie
030220 oncology & carcinogenesis
Female
business
Triptorelin Pamoate -- administration & dosage
Hématologie
Zdroj: Journal of clinical oncology, 34 (22
ISSN: 1527-7755
0732-183X
DOI: 10.1200/jco.2015.65.8864
Popis: We have reported previously that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemotherapy-induced premature ovarian failure (POF) in patients with lymphoma, but may provide protection of the ovarian reserve. Here, we report the final analysis of the cohort after 5 years of follow up.
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: